%A McGeer,Patrick %A McGeer,Edith %D 2011 %J Frontiers in Pharmacology %C %F %G English %K Alzheimer Disease,complement,HLA-DR,Neuroinflammation,Parkinson Disease %Q %R 10.3389/fphar.2011.00077 %W %L %M %P %7 %8 2011-December-02 %9 Mini Review %+ Dr Patrick McGeer,University of British Columbia,Vancouver,Canada,mcgeerpl@interchange.ubc.ca %+ Dr Edith McGeer,University of British Columbia,Vancouver,Canada,mcgeer@interchange.ubc.ca %# %! History of Innate Immunity in Neurodegenerative Disorders %* %< %T History of Innate Immunity in Neurodegenerative Disorders %U https://www.frontiersin.org/articles/10.3389/fphar.2011.00077 %V 2 %0 JOURNAL ARTICLE %@ 1663-9812 %X The foundations of innate immunity in neurodegenerative disorders were first laid by Del Rio Hortega (1919). He identified and named microglia, recognizing them as cells of mesodermal origin. Van Furth in 1969 elaborated the monocyte phagocytic system with microglia as the brain representatives. Validation of these concepts did not occur until 1987 when HLA-DR was identified on activated microglia in a spectrum of neurological disorders. HLA-DR had already been established as a definitive marker of immunocompetent cells of mesodermal origin. It was soon determined that the observed inflammatory reaction was an innate immune response. A rapid expansion of the field took place as other markers of an innate immune response were found that were made by neurons, astrocytes, oligodendroglia, and endothelial cells. The molecules included complement proteins and their regulators, inflammatory cytokines, chemokines, acute phase reactants, prostaglandins, proteases, protease inhibitors, coagulation factors, fibrinolytic factors, anaphylatoxins, integrins, free radical generators, and other unidentified neurotoxins. The Nimmerjahn movies demonstrated that resting microglia were constantly active, sampling the surround, and responding rapidly to brain damage. Ways of reducing the neurotoxic innate immune response and stimulating a healing response continue to be sought as a means for ameliorating the pathology in a spectrum of chronic degenerative disorders.